Loutfy MR - Search Results

1

Treatment of HIV infection in pregnant women: antiretroviral management options.

Loutfy MR, Walmsley SL. Loutfy MR, et al. Drugs. 2004;64(5):471-88. doi: 10.2165/00003495-200464050-00002. Drugs. 2004. PMID: 14977385 Review.

2

Salvage antiretroviral therapy in HIV infection.

Loutfy MR, Walmsley SL. Loutfy MR, et al. Expert Opin Pharmacother. 2002 Feb;3(2):81-90. doi: 10.1517/14656566.3.2.81. Expert Opin Pharmacother. 2002. PMID: 11829722 Review.

3

Inclusion body myositis: another possible manifestation of antiretroviral-associated mitochondrial toxicity.

Loutfy MR, Sheehan NL, Goodhew JE, Walmsley SL. Loutfy MR, et al. AIDS. 2003 May 23;17(8):1266-7. doi: 10.1097/01.aids.0000060401.18106.ba. AIDS. 2003. PMID: 12819534 No abstract available.

4

Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?

Walmsley S, Loutfy M. Walmsley S, et al. J Int Assoc Physicians AIDS Care (Chic). 2002 Summer;1(3):95-103. doi: 10.1177/154510970200100304. J Int Assoc Physicians AIDS Care (Chic). 2002. PMID: 12942682 Review.

5

Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.

Loutfy M, Raboud J, Thompson C, Tseng A, Abdurrahman Z, Kovacs C, Rachlis A, Phillips E, Rubin G, Gough K, Walmsley S. Loutfy M, et al. HIV Clin Trials. 2003 Sep-Oct;4(5):301-10. doi: 10.1310/7LYW-GQFF-WPRQ-K3QW. HIV Clin Trials. 2003. PMID: 14583846

6

Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.

Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, Hogg RS, Thompson CA, Harrigan PR. Loutfy MR, et al. Antivir Ther. 2004 Aug;9(4):595-602. Antivir Ther. 2004. PMID: 15456091

7

CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy.

Loutfy MR, Walmsley SL, Mullin CM, Perez G, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS; Canada HIV Trials Network. Loutfy MR, et al. J Infect Dis. 2005 Oct 15;192(8):1407-11. doi: 10.1086/466537. Epub 2005 Sep 9. J Infect Dis. 2005. PMID: 16170758

8

A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164).

Walmsley SL, Thorne A, Loutfy MR, LaPierre N, MacLeod J, Harrigan R, Trottier B, Conway B, Hay JR, Singer J, Zarowny D. Walmsley SL, et al. Among authors: loutfy mr. J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):418-25. doi: 10.1097/QAI.0b013e318061b611. J Acquir Immune Defic Syndr. 2007. PMID: 17468667 Clinical Trial.

9

Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.

Loutfy MR, Ackad N, Antoniou T, Baril JG, Conway B, de Wet J, Trottier B, Kovacs CM, Thompson W, Martel AY, Trottier S, Rouleau D, Shafran SD, Rachlis A, Fraser C, Smaill F, Walmsley SL, Tseng AL, Sampalis JS. Loutfy MR, et al. HIV Clin Trials. 2007 Sep-Oct;8(5):259-68. doi: 10.1310/hct0805-259. HIV Clin Trials. 2007. PMID: 17956827 Clinical Trial.

10

Predictive value of immune parameters before treatment interruption (TI) for CD4+ T-cell count change during TI in HIV infection.

Huang KH, Loutfy MR, Boulet S, Toma E, Tsoukas CM, Bernard NF. Huang KH, et al. Among authors: loutfy mr. Antivir Ther. 2009;14(3):381-92. Antivir Ther. 2009. PMID: 19474472

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

354 results

Search Page

Filters